Sugi Predict

Sugi Predict / Compounds / SCHEMBL268078

SCHEMBL268078

SCHEMBL268078

Cc1cc(F)ccc1C[C@@H](N)[C@@H](O)Cc1ncccc1C(=O)NC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ANO1 Q5XXA6 6/20 0.38
▸ ALOX5AP P20292 2/20 0.38
▸ FEN1 P39748 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ EIF2S1 P05198 1/20 0.37
▸ EIF2AK3 Q9NZJ5 1/20 0.37
▸ NR3C2 P08235 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ ESR1 P03372 1/20 0.35
▸ SGMS2 Q8NHU3 1/20 0.35
▸ P2RX7 Q99572 1/20 0.34
▸ CARM1 Q86X55 1/20 0.34
▸ PRMT6 Q96LA8 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268007 0.93 SGMS2 (0.40) ANO1ALOX5APFEN1SMN1; SMN2EIF2S1
SCHEMBL269072 0.92 ALOX5AP (0.40) ANO1ALOX5APFEN1SMN1; SMN2LMNA
SCHEMBL267905 0.91 ANO1 (0.42) ANO1ALOX5APFEN1SMN1; SMN2ALDH1A1
SCHEMBL269498 0.90 ALOX5AP (0.38) ANO1ALOX5APFEN1SMN1; SMN2EIF2S1
SCHEMBL270520 0.90 ALOX5AP (0.40) ANO1ALOX5APFEN1SMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL3989995 0.90 ALOX5AP (0.39) ANO1ALOX5APFEN1SMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL269767 0.90 ALOX5AP (0.39) ANO1ALOX5APFEN1SMN1; SMN2LMNA
SCHEMBL267895 0.89 ANO1 (0.46) ANO1ALOX5APFEN1SMN1; SMN2LMNA
SCHEMBL270276 0.88 SMN1; SMN2 (0.42) ANO1ALOX5APFEN1SMN1; SMN2NR3C2
Hydrochloric Acid SCHEMBL270358 0.88 ANO1 (0.45) ANO1ALOX5APFEN1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133907-B2 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin ELI LILLY AND COMPANY (US) 2012-03-13 — — US disclosed
EP-1912946-B1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS LILLY CO ELI (US) 2009-05-27 — — EP disclosed
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors ELI LILLY AND COMPANY 2008-09-04 — — US disclosed
EP-1912946-A1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS Eli Lilly and Company (US) 2008-04-23 — — EP disclosed
WO-2007015767-A1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors DPP4, DPP3, DPP7 ANO1 3344/4885ALOX5AP 3715/4885FEN1 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.